| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | PDE7A, phosphodiesterase 7A |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| UniProt # |
Scientific Background
Phosphodiesterases (PDEs) regulate the intracellular levels of cAMP and cGMP by hydrolyzing cAMP and cGMP to their inactive 5' monophosphates. These cyclic nucleotides play an important role as second messengers in diverse physiological functions. PDE7 is a cAMP-specific enzyme and two PDE genes (PDE7A and PDE7B) have been identified. PDE7 is widely expressed in various tissues, with PDE7A found primarily in skeletal muscle, T lymphocytes, and pancreas, while high levels of PDE7B are detected in brain, heart, and liver. Inhibition of PDE7 activity by its inhibitors leads to elevated intracellular level of cAMP.
Product Description
PhosphodiesteraseRecombinant HEK293 cell line expressing human PDE7A (phosphodiesterase 7A, accession number NM_002603). N-terminal FLAG-tagged human PDE7A has been stably expressed in a human embryonic kidney (HEK293) cell line. PDE7A expression was confirmed by Western blotting. The regulation of intracellular level of cAMP by PDE7A in PDE7A stably-expressed HEK293 cells was characterized by a cell-based reporter assay using pCRE-luc reporter vector. pCRE-luc contains a luciferase gene that is under the control of the cAMP response element (CRE). When cells transiently transfected with pCRE-luc reporter were activated by forskolin, the level of cAMP was upregulated in parental HEK293 cells, inducing the expression of the luciferase reporter, whereas hPDE7A-HEK293 cells showed reduction in the level of cAMP that resulted in lowered expression of luciferase. Inhibition of PDE7A activity by BRL 50481, a PDE7A inhibitor, restored the cAMP level, resulting in higher luciferase activity.
Product Specifications
| Host Cell Line | HEK293 |
|---|---|
| Host Species | Human |
| Transfection Method | Lipofectamine 2000 |
| Format | Aqueous solution containing DMSO |
| Supplied As | Each vial contains ~1 X 10^6 cells in 1 ml of 10% DMSO. |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThe cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma Aldrich) to confirm the absence of Mycoplasma species.
Usage Notes
See data sheet for detailed culturing and assay protocol.
Safety & Handling
⚠ Avoid freeze/thaw cycles.
Regulatory Information
License Disclosure
This product is engineered on a HEK293 background (Human origin). The HEK293 host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-2. Work must be performed in a certified BSL-2 laboratory by trained personnel. All procedures that may generate aerosols must be conducted inside a Class II Biological Safety Cabinet. Institutional Biosafety Committee (IBC) approval is required before use.
Yes. The cell line has been screened using the PCR-based Venor™GeM Mycoplasma Detection kit (Sigma Aldrich) to confirm the absence of Mycoplasma species. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Store in liquid nitrogen immediately upon receipt. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Malik, R. et al. (2008) Appl. Microbiol. Biotechnol. 77 (5): 1167-1173.
- Fan Chung, K. (2006). Eur. J. Pharmacol. 533(1-3):110-117.